Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Goodwill (2016 - 2026)

Ani Pharmaceuticals' Goodwill history spans 13 years, with the latest figure at $62.5 million for Q4 2025.

  • On a quarterly basis, Goodwill rose 4.15% to $62.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.5 million, a 4.15% increase, with the full-year FY2025 number at $62.5 million, up 4.15% from a year prior.
  • Goodwill hit $62.5 million in Q4 2025 for Ani Pharmaceuticals, roughly flat from $62.5 million in the prior quarter.
  • Over the last five years, Goodwill for ANIP hit a ceiling of $62.5 million in Q3 2025 and a floor of $3.6 million in Q1 2021.
  • Historically, Goodwill has averaged $34.4 million across 5 years, with a median of $28.2 million in 2022.
  • Biggest five-year swings in Goodwill: changed 0.0% in 2021 and later skyrocketed 688.3% in 2022.
  • Tracing ANIP's Goodwill over 5 years: stood at $27.9 million in 2021, then grew by 1.08% to $28.2 million in 2022, then increased by 0.07% to $28.2 million in 2023, then surged by 112.57% to $60.0 million in 2024, then increased by 4.15% to $62.5 million in 2025.
  • Business Quant data shows Goodwill for ANIP at $62.5 million in Q4 2025, $62.5 million in Q3 2025, and $60.5 million in Q2 2025.